Effects of ampicillin, gentamicin, and cefotaxime on the release of shiga toxins from shiga toxin-producing escherichia coli isolated during a diarrhea episode in Faisalabad, Pakistan

Foodborne Pathogens and Disease

Volumn 7, Issue 1, 2010, Pages 85-90

  Mohsin, Mashkoor ^a   Haque, Abdul ^a   Ali, Aamir ^a   Sarwar, Yasra ^a   Bashir, Saira ^a   Tariq, Ayesha ^a   Afzal, Amna ^a   Iftikhar, Tayyaba ^a   Saeed, Muhammad Azeem ^a  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; GENTAMICIN; SHIGA TOXIN;

ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PAKISTAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

ADHESINS, BACTERIAL; AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DYSENTERY; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GENTAMICINS; HEMOLYSIN PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PAKISTAN; PHENOTYPE; SHIGA TOXINS; SHIGA-TOXIGENIC ESCHERICHIA COLI; VERO CELLS; VIRULENCE;

ESCHERICHIA COLI;

EID: 74549162157     PISSN: 15353141     EISSN: None     Source Type: Journal    
DOI: 10.1089/fpd.2009.0311     Document Type: Article

References (28)

1. Bettelheim KA and Beutin L. Rapid laboratory identification and characterization of verocytotoxigenic (Shiga toxin producing) Escherichia coli (VTEC=STEC). J Appl Microbiol 2003;95:205-217.
2. Diniz-Santos DR, Silva LR, and Silva N. Antibiotics for the empirical treatment of acute infectious diarrhea in children. Braz J Infect Dis 2006;10:217-227.
3. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, and Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001;33:923-931.
4. Fach P, Perelle S, Grout J, and Dilasser F. Comparison of different PCR tests for detecting Shiga toxin-producing Escherichia coli O157 and development of an ELISA-PCR assay for specific identification of the bacteria. J Microbiol Methods 2003;55:383-392. (Pubitemid 37177036)
5. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, and Karch H. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002;185:74-84.
6. Grif K, Dierich MP, Karch H, and Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998;17:761-766.
7. Iijima K, Kamioka I, and Nozu K. Management of diarrheaassociated hemolytic uremic syndrome in children. Clin Exp Nephrol 2008;12:16-19.
8. Ito T, Akino E, and Hiramatsu K. [Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis-effect of various antibiotics on extracellular release of verotoxin]. Kansenshogaku Zasshi 1997;71:130-135.
9. Johnson KE, Thorpe CM, and Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis 2006;43:1587-1595.
10. Kimmitt PT, Harwood CR, and Barer MR. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 2000;6:458-465.
11. Mohsin M, Hussain A, Butt MA, Bashir S, Tariq A, Babar S, Ali A, Haque A, Sarwar Y, and Haque A. Prevalence of Shiga Toxin-Producing Escherichia coli in diarrheal patients in Faisalabad region of Pakistan as determined by multiplex PCR. J Infect Dev Ctries 2007;1:164-169.
12. Mufti P, Bhutta ZA, and Hasan R. Acute gastroenteritis caused by E. coli O.157:H7 in Pakistani children. J Trop Pediatr 1999;45:253-254.
13. Murakami J, Kishi K, Hirai K, Hiramatsu K, Yamasaki T, and Nasu M. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 2000;15:103-109.
14. NCCLS (National committee for Clinical and Laboratory Standards). Methods for Dilution Antimicrobial susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Fifth Edition, NCCLS Document M7-A5. Wayne, PA; NCCLS, 2000.
15. Panos GZ, Betsi GI, and Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 2006;24:731-742.
16. Pedersen MG, Hansen C, Riise E, Persson S, and Olsen KE. Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol 2008;46:2987-2991.
17. Ramotar K, Waldhart B, Church D, Szumski R, and Louie TJ. Direct detection of verotoxin-producing Escherichia coli in stool samples by PCR. J Clin Microbiol 1995;33:519-524.
18. Safdar N, Said A, Gangnon RE, and Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. JAMA 2002;288:996-1001. (Pubitemid 34920465)
19. Schmidt H, Beutin L, and Karch H. Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933. Infect Immun 1995;63:1055-1061.
20. Shibl AM. Selective inhibition of enzyme synthesis by lincomycin in Staphylococcus aureus. J Antimicrob Chemother 1984;13: 625-627.
21. Tarr PI, Gordon CA, and Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-1086.
22. Thorpe CM. Shiga toxin-producing Escherichia coli infection. Clin Infect Dis 2004;38:298-1303.
23. Walterspiel JN, Ashkenazi S, Morrow AL, and Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992;20:25-29.
24. Wong CS, Jelacic S, Habeeb RL, Watkins SL, and Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930-1936.
25. Yoh M, Frimpong EK, and Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol 1997b;19:57-64. (Pubitemid 27402031)
26. Yoh M and Honda T. The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production=release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157: H7 in vitro. Epidemiol Infect 1997a;119:101-103.
27. Zhang WL, Kohler B, Oswald E, Beutin L, Karch H, Morabito S, Caprioli A, Suerbaum S, and Schmidt H. Genetic diversity of intimin genes of attaching and effacing Escherichia coli strains. J Clin Microbiol 2002;40:4486-4492.
28. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, and Acheson DW. Quinolone antibiotics induce Shiga toxinencoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000;181:664-670.